In vitro and in vivo study on the antioxidant activity of dexrazoxane

Biomedicine and Pharmacotherapy

Volumn 64, Issue 4, 2010, Pages 259-263

  Galetta, Fabio ^a   Franzoni, Ferdinando ^a   Cervetti, Giulia ^b   Regoli, Francesco ^d   Fallahi, Poupak ^a   Tocchini, Leonardo ^a   Carpi, Angelo ^c   Antonelli, Alessandro ^a   Petrini, Mario ^b   Santoro, Gino ^a  

^a Department of Internal Medicine ^*  (Italy)

^b Transplants and New Technologies in Medicine   (Italy)

^c UNIVERSITY OF PISA   (Italy)

^d UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

Author keywords

Anthracyclines; Antioxidants; Dexrazoxane; Epirubicin; Free radicals

Indexed keywords

BLEOMYCIN; CYCLOPHOSPHAMIDE; CYTARABINE; EPIRUBICIN; ETOPOSIDE; FREE RADICAL; GLUTATHIONE; METHOTREXATE; PREDNISOLONE; RAZOXANE; TROLOX C; URIC ACID; VINCRISTINE;

ADULT; ANTIOXIDANT ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MALE; MULTIPLE CYCLE TREATMENT; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ANTIOXIDANTS; BLEOMYCIN; CHROMANS; CYCLOPHOSPHAMIDE; CYTARABINE; EPIRUBICIN; ETOPOSIDE; FEMALE; FREE RADICAL SCAVENGERS; GLUTATHIONE; HUMANS; LYMPHOMA, NON-HODGKIN; MALE; METHOTREXATE; MIDDLE AGED; PREDNISONE; RAZOXANE; TIME FACTORS; URIC ACID; VINCRISTINE;

EID: 77952319706     PISSN: 07533322     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biopha.2009.06.018     Document Type: Article

References (31)

1. Lenaz L., Page J. Cardiotoxicity of adriamycin and related anthracyclines. Cancer Treat Rev 1976, 3:111-120.
2. Lefrak E.A., Pitha J., Rosenheim S., Gottlieb J.A. A clinicopathologic analysis of doxorubicin cardiotoxicity. Cancer 1973, 32:302-314.
3. Grenier M.A., Lipshultz S.E. Epidemiology of anthracycline cardiotoxicity in children and adults. Semin Oncol 1998, 25:72-85.
4. Lipshultz S.E., Lipsitz S.R., Sallan S.E., Dalton V.M., Mone S.M., Gelber R.D., et al. Chronic progressive cardiac dysfunction years after doxorubicin therapy for childhood acute lymphoblastic leukemia. J Clin Oncol 2005, 23:2629-2636.
5. Olson R., Mushlin P. Doxorubicin cardiotoxicity: analysis of prevailing hypothesis. FASEB J 1990, 4:3076-3086.
6. Lebrecht D., Geist A., Ketelsen J., Setter B., Walzer U.A. Dexrazoxane prevents doxorubicin-induced long-term cardiotoxicity and protects myocardial mitochondria from genetic and functional lesions in rats. Br J Pharmacol 2007, 151:771-778.
7. Gianni L., Zweier J., Levy A., Meyers C.E. Characterization of the cycle of iron-mediated electron transfer from doxorubicin to molecular oxygen. J Biol Chem 1985, 259:6056-6058.
8. Vile G.F., Winterbourn C.C. dl-N,N'-dicarboxamidomethyl-N,N'-dicarboxy methyl-1,2-diaminopropane (ICRF-198) and d-1,2-bis(3,5-dioxopiperazine- 1-yl)propane (ICRF-187) inhibition of Fe3+ reduction, lipid peroxidation, and CaATPase inactivation in heart microsomes exposed to adriamycin. Cancer Res 1990, 50:2307-2310.
9. Cvetković R.S., Scott L.J. Dexrazoxane: a review of its use for cardioprotection during anthracycline chemotherapy. Drugs 2005, 65:1005-1024.
10. Pouillart P. Evaluating the role of dexrazoxane as a cardioprotectant in cancer patients receiving anthracyclines. Cancer Treat Rev 2004, 30:643-650.
11. Speyer J.L., Green M.D., Zeleniuch-Jacquotte A., Wernz J.C., Rey M., Sanger J., et al. ICRF-187 permits longer treatment with doxorubicin in women with breast cancer. J Clin Oncol 1992, 10:117-127.
12. Swain S.M., Whaley F.S., Gerber M.C., Weisberg S., York M., Spicer D., et al. Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer. J Clin Oncol 1997, 15:1318-1332.
13. Swain S.M., Whaley F.S., Gerber M.C., Ewer M.S., Bianchine J.R., Gams R.A. Delayed administration of dexrazoxane provides cardioprotection for patients with advanced breast cancer treated with doxorubicin-containing therapy. J Clin Oncol 1997, 15:1333-1340.
14. Venturini M., Michelotti A., Del Mastro L., Gallo L., Carnino F., Garrone O., et al. Multicenter randomized controlled clinical trial to evaluate cardio-protection of dexrazoxane versus no cardio-protection in women receiving epirubicin chemotherapy for advanced breast cancer. J Clin Oncol 1996, 14:3112-3120.
15. Anderson B. Dexrazoxane for the prevention of cardiomyopathy in anthracycline treated pediatric cancer patients. Pediatr Blood Cancer 2005, 44:584-588.
16. Wexler L.H., Andrich M.P., Venzon D., Berg S.L., Weaver-McClure L., Chen C.C., et al. Randomized trial of the cardioprotective agent ICRF-187 in pediatric sarcoma patients treated with doxorubicin. J Clin Oncol 1996, 14:362-372.
17. Lipshultz S.E., Rifai N., Dalton V.M., Levy D.E., Silverman L.B., Lipsitz S.R., et al. The effect of dexrazoxane on myocardial injury in doxorubicin-treated children with acute lymphoblastic leukemia. N Engl J Med 2004, 351:145-153.
18. Oken M.M., Creech R.H., Tormey D.C., Horton J., Davis T.E., McFadden E.T., et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982, 5:649-655.
19. Regoli F., Winston G.W. Quantification of total oxidant scavenging capacity (TOSC) of antioxidants for peroxynitrite, peroxyl radicals and hydroxyl radicals. Toxicol Appl Pharmacol 1999, 156:96-105.
20. Franzoni F., Quinones-Galvan A., Regoli F., Ferrannini E., Galetta F. A comparative study of the in vitro antioxidant activity of statins. Int J Cardiol 2003, 90:317-321.
21. Ferrans V.J. Overview of cardiac pathology in relation to anthracycline cardiotoxicity. Cancer Treat Rep 1978, 62:955-961.
22. Galetta F., Franzoni F., Cervetti G., Cecconi N., Carpi A., Petrini M., et al. Effect of epirubicin-based chemotherapy and dexrazoxane supplementation on QT dispersion in non-Hodgkin lymphoma patients. Biomed Pharmacother 2005, 59:541-544.
23. Basser R.L., Green M.D. Strategies for prevention of anthracycline cardiotoxicity. Cancer Treat Rev 1993, 19:55-77.
24. Zweier J.L., Gianni L., Muindi J., Myers C.E. Differences in O2 reduction by iron complexes of adriamycin and daunorubicin: the importance of sidechain hydroxyl group. Biochem Biophys Acta 1986, 884:326-336.
25. Hasinoff B.B. The interaction of the cardioprotective cardioxane (ICRF-197); its hydrolysis product (ICRF-198) and other chelating agents with the Fe (III) and Cu (II) complexes of adriamycin. Agents Action Suppl 1989, 26:378-385.
26. Marty M., Espié M., Llombart A., Monnier A., Rapoport B.L., Stahalova V., et al. Multicenter randomized phase III study of the cardioprotective effect of dexrazoxane (Cardioxane) in advanced/metastatic breast cancer patients treated with anthracycline-based chemotherapy. Ann Oncol 2006, 17:614-622.
27. Wiseman L.R., Spencer C.M. Dexrazoxane. A review of its use as a cardioprotective agent in patients receiving anthracycline-based chemotherapy. Drugs 1998, 56:385-403.
28. Hasinoff B.B., Hellmann K., Hermann E.H., Ferrans V.J. Chemical, biological, and clinical aspects of dexrazoxane and other bisdioxopiperazines. Curr Med Chem 1998, 5:1-28.
29. Carr A, Frei B. Does vitamin C act as a pro-oxidant under physiological conditions?. FASEB J 1999, 13:1007-1024.
30. Stocker R. The ambivalence of vitamin E in atherogenesis. Trends Biochem Sci 1999, 24:219-223.
31. Winston G.W., Regoli F., Dugas A.J., Fong J.H., Blanchard K.A. A rapid gas chromatographic assay for determining oxyradical scavenging capacity of antioxidants and biological fluids. Free Radicals Biol Med 1998, 24:480-493.